Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox approved in Portugal and Switzerland

Jun 25, 2018Mark EdwardsNews

25 June 2018

ASX Announcement

Penthrox approved in Portugal and Switzerland.

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Switzerland and Portugal.

MVP CEO, Mr. John Sharman said, ?The roll out of Penthrox across Europe continues. We are delighted to have received the approval from Switzerland which is not part of the EU and therefore conducted its own independent assessment of Penthrox. We expect sales to commence in these markets during FY19.?

Refer to the following link for the full announcement – Penthrox approved in Switzerland and Portugal

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

  • MVP Board Re-organisation

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.